VIR BIOTECHNOLOGY INC (VIR)
US92764N1028 - Common Stock
Noteworthy Friday Option Activity: GSAT, VIR, INTC
Top movers in Friday's session
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Vir Biotechnology Becomes Oversold (VIR)
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vir Biotechnology (NASDAQ:VIR) just reported results for the second quarter of ...
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
Notable Two Hundred Day Moving Average Cross - VIR
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient...
VIR Crosses Above Key Moving Average Level
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vir Biotechnology (NASDAQ:VIR) just reported results for the first quarter of 2...
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
